Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation
- PMID: 12357247
- DOI: 10.1038/nm781
Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation
Abstract
During mammalian central nervous system (CNS) development, contact-mediated activation of Notch1 receptors on oligodendrocyte precursors by the ligand Jagged1 induces Hes5, which inhibits maturation of these cells. Here we tested whether the Notch pathway is re-expressed in the adult CNS in multiple sclerosis (MS), an inflammatory demyelinating disease in which remyelination is typically limited. We found that transforming growth factor-beta 1 (TGF-beta 1), a cytokine upregulated in MS, specifically re-induced Jagged1 in primary cultures of human astrocytes. Within and around active MS plaques lacking remyelination, Jagged1 was expressed at high levels by hypertrophic astrocytes, whereas Notch1 and Hes5 localized to cells with an immature oligodendrocyte phenotype, and TGF-beta 1 was associated with perivascular extracellular matrix in the same areas. In contrast, there was negligible Jagged1 expression in remyelinated lesions. Experiments in vitro showed that Jagged1 signaling inhibited process outgrowth from primary human oligodendrocytes. These data are the first to implicate the Notch pathway in the limited remyelination in MS. Thus, Notch may represent a potential target for therapeutic intervention in this disease.
Comment in
-
Myelin failure in multiple sclerosis: breaking the spell of Notch.Nat Med. 2002 Oct;8(10):1075-6. doi: 10.1038/nm1002-1075. Nat Med. 2002. PMID: 12357237 No abstract available.
Similar articles
-
Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination.Brain. 2004 Sep;127(Pt 9):1928-41. doi: 10.1093/brain/awh217. Epub 2004 Aug 2. Brain. 2004. PMID: 15289265
-
Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination.Acta Neuropathol. 2007 Feb;113(2):195-203. doi: 10.1007/s00401-006-0170-9. Epub 2006 Nov 30. Acta Neuropathol. 2007. PMID: 17136549
-
TGFbeta1 induces Jagged1 expression in astrocytes via ALK5 and Smad3 and regulates the balance between oligodendrocyte progenitor proliferation and differentiation.Glia. 2010 Jun;58(8):964-74. doi: 10.1002/glia.20978. Glia. 2010. PMID: 20169621 Free PMC article.
-
Notch signalling pathway and human diseases.Semin Cell Dev Biol. 1998 Dec;9(6):619-25. doi: 10.1006/scdb.1998.0261. Semin Cell Dev Biol. 1998. PMID: 10075489 Review.
-
Axoglial interaction via the notch receptor in oligodendrocyte differentiation.Ann Acad Med Singap. 2004 Sep;33(5):581-8. Ann Acad Med Singap. 2004. PMID: 15531953 Review.
Cited by
-
Activation of endogenous neural stem cells for multiple sclerosis therapy.Front Neurosci. 2015 Jan 20;8:454. doi: 10.3389/fnins.2014.00454. eCollection 2014. Front Neurosci. 2015. PMID: 25653584 Free PMC article.
-
Myelination in Multiple Sclerosis Lesions Is Associated with Regulation of Bone Morphogenetic Protein 4 and Its Antagonist Noggin.Int J Mol Sci. 2019 Jan 3;20(1):154. doi: 10.3390/ijms20010154. Int J Mol Sci. 2019. PMID: 30609838 Free PMC article.
-
Remyelination strategies: new advancements toward a regenerative treatment in multiple sclerosis.Curr Neurol Neurosci Rep. 2006 May;6(3):229-35. doi: 10.1007/s11910-006-0010-2. Curr Neurol Neurosci Rep. 2006. PMID: 16635432 Review.
-
Multiple Sclerosis and Aging: The Dynamics of Demyelination and Remyelination.ASN Neuro. 2022 Jan-Dec;14:17590914221118502. doi: 10.1177/17590914221118502. ASN Neuro. 2022. PMID: 35938615 Free PMC article. Review.
-
Cell therapy for multiple sclerosis.Neurotherapeutics. 2011 Oct;8(4):625-42. doi: 10.1007/s13311-011-0073-x. Neurotherapeutics. 2011. PMID: 21904787 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous